# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Li Watsek initiates coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) with a Overweight rating and ann...
Canaccord Genuity analyst Bill Maughan maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and maintains $26 price target.
Morgan Stanley analyst Michael Ulz maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Underweight and lowers the price targe...
HC Wainwright & Co. analyst Robert Burns reiterates Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and maintains $22 price...
BMO Capital analyst Etzer Darout maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Outperform and lowers the price target f...
Anticipated Operating Expenses expected to remain between $115 million and $120 million;Anticipated Total Annual Cash Burn expe...